C
Camila Covián
Researcher at Pontifical Catholic University of Chile
Publications - 11
Citations - 568
Camila Covián is an academic researcher from Pontifical Catholic University of Chile. The author has contributed to research in topics: Vaccination & Immunity. The author has an hindex of 6, co-authored 11 publications receiving 257 citations. Previous affiliations of Camila Covián include University of Antofagasta & Millennium Institute.
Papers
More filters
Journal ArticleDOI
BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design
Camila Covián,Camila Covián,Ayleen Fernández-Fierro,Angello Retamal-Díaz,Fabián E. Díaz,Abel E. Vasquez,Margarita K. Lay,Margarita K. Lay,Claudia A. Riedel,Pablo A. González,Susan M. Bueno,Alexis M. Kalergis +11 more
TL;DR: BCG-induced cross-protection and acquisition of trained immunity and potential heterologous effects of recombinant BCG vaccines are discussed.
Journal ArticleDOI
Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
TL;DR: Interestingly, those countries where BCG vaccination is given at birth have shown a lower contagion rate and fewer COVID-19-related deaths, suggesting that this vaccine may induce trained immunity that could confer some protection for SARS-CoV-2.
Journal ArticleDOI
Naturally Derived Heme-Oxygenase 1 Inducers and Their Therapeutic Application to Immune-Mediated Diseases.
Samanta C. Funes,Mariana Ríos,Ayleen Fernández-Fierro,Camila Covián,Susan M. Bueno,Claudia A. Riedel,Juan Pablo Mackern-Oberti,Juan Pablo Mackern-Oberti,Alexis M. Kalergis +8 more
TL;DR: It is concluded that the use of some compounds from natural sources able to induce HO-1 is an attractive lifestyle toward promoting human health and opens a new outlook on the investigation of naturally derivedHO-1 inducers, mainly concerning autoimmunity.
Journal ArticleDOI
Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile.
Susan M. Bueno,Susan M. Bueno,Katia Abarca,Katia Abarca,Pablo A. González,Pablo A. González,Nicolás M. S. Gálvez,Nicolás M. S. Gálvez,Jorge A. Soto,Jorge A. Soto,Luisa F. Duarte,Luisa F. Duarte,Bárbara M. Schultz,Bárbara M. Schultz,Gaspar A. Pacheco,Gaspar A. Pacheco,Liliana A. González,Liliana A. González,Yaneisi Vázquez,Yaneisi Vázquez,Mariana Ríos,Mariana Ríos,Felipe Melo-González,Felipe Melo-González,Daniela Rivera-Pérez,Daniela Rivera-Pérez,Carolina Iturriaga,Marcela Urzúa,Angélica Domínguez,Catalina A. Andrade,Catalina A. Andrade,Roslye V Berrios,Roslye V Berrios,Gisela Canedo-Marroquín,Gisela Canedo-Marroquín,Camila Covián,Camila Covián,Daniela Moreno-Tapia,Daniela Moreno-Tapia,Farides Saavedra,Farides Saavedra,Omar P. Vallejos,Omar P. Vallejos,Paulina Donato,Pilar Espinoza,Daniela Fuentes,Marcela Gonzalez,Paula Guzman,Paula Muñoz-Venturelli,Carlos M Perez,Marcela Potin,Álvaro Rojas,Rodrigo Fasce,Jorge Fernández,Judith Mora,Eugenio Ramírez,Aracelly Gaete-Argel,Aarón Oyarzún-Arrau,Fernando Valiente-Echeverría,Ricardo Soto-Rifo,Daniela Weiskopf,Alessandro Sette,Gang Zeng,Weining Meng,José Vicente González-Aramundiz,Alexis M. Kalergis,Alexis M. Kalergis +66 more
TL;DR: CoronaVac as discussed by the authors is an inactivated SARS-CoV-2 vaccine with promising safety and immunogenicity profiles, which was used in a phase 3 clinical trial in Chile.
Posted ContentDOI
Interim Report: Safety And Immunogenicity Of An Inactivated Vaccine Against Sars-Cov-2 In Healthy Chilean Adults In A Phase 3 Clinical Trial
Susan M. Bueno,Susan M. Bueno,Katia Abarca,Katia Abarca,Pablo A. González,Pablo A. González,Nicolás M. S. Gálvez,Nicolás M. S. Gálvez,Jorge A. Soto,Jorge A. Soto,Luisa F. Duarte,Luisa F. Duarte,Bárbara M. Schultz,Bárbara M. Schultz,Gaspar A. Pacheco,Gaspar A. Pacheco,Liliana A. González,Liliana A. González,Yaneisi Vasquez,Yaneisi Vasquez,Mariana Ríos,Mariana Ríos,Felipe Melo-González,Felipe Melo-González,Daniela Rivera-Pérez,Daniela Rivera-Pérez,Carolina Iturriaga,Marcela Urzúa,Angélica Domínguez,Catalina A. Andrade,Catalina A. Andrade,Roslye V Berrios,Roslye V Berrios,Gisela Canedo-Marroquín,Gisela Canedo-Marroquín,Camila Covián,Camila Covián,Daniela Moreno-Tapia,Daniela Moreno-Tapia,Farides Saavedra,Farides Saavedra,Omar P. Vallejos,Omar P. Vallejos,Paulina Donato,Pilar Espinoza,Daniela Fuentes,Marcela Gonzalez,Paula Guzman,Paula Muñoz-Venturelli,Carlos M Perez,Marcela Potin,Álvaro Rojas,Rodrigo Fasce,Jorge Fernández,Judith Mora,Eugenio Ramírez,Aracelly Gaete-Argel,Aarón Oyarzún-Arrau,Fernando Valiente-Echeverría,Ricardo Soto-Rifo,Daniela Weiskopf,Alessandro Sette,Gang Zeng,Weining Meng,José Vicente González-Aramundiz,Alexis M. Kalergis,Alexis M. Kalergis +66 more
TL;DR: The authors in this paper reported the safety and immunogenicity results obtained in a subgroup of participants aged 18 years and older enrolled in the phase 3 Clinical Trial held in Chile.